The World Health Organisation has begun supporting a new clinical trial to determine whether existing and experimental vaccines can protect against the Bundibugyo strain of Ebola, as the Democratic Republic of the Congo battles a major outbreak that has killed more than 4,600 people.
The trial, named Tumaini, meaning “hope” in Swahili, began on Friday, October 23, after the first participants received vaccinations in Bunia, the capital of Ituri province in northeastern DR Congo. The area is at the centre of the ongoing outbreak.
WHO Director-General Tedros Adhanom Ghebreyesus announced the development, describing the trial as an important step towards establishing whether vaccine candidates can protect people against the virus responsible for the current outbreak.
The study is being led by Congolese authorities and research institutions, with technical and scientific support from the WHO and other international partners.
The first vaccine being tested is Ervebo, which is already licensed to prevent Ebola disease caused by the Zaire strain of the virus. Researchers will investigate whether it can also provide protection against the Bundibugyo strain, for which no vaccine has been approved.
Although Ervebo has been used in responses to previous Ebola outbreaks, its effectiveness against Bundibugyo has not been established. The trial is therefore expected to provide critical evidence that could guide decisions on how best to protect people exposed to the virus.
Two additional vaccine candidates are expected to join the study as their development progresses. One is being developed by Moderna, while the other uses the ChAdOx1 vaccine technology developed by the University of Oxford in collaboration with the Serum Institute of India.
The candidates are designed to address the Bundibugyo virus, and their inclusion could expand the options available to health authorities if they demonstrate sufficient safety and effectiveness.
The Tumaini trial will assess vaccine safety, immune responses and protection against the disease. Researchers will use a ring vaccination approach, focusing on contacts of confirmed Ebola cases and other people considered to be at high risk of infection.
The study is also expected to include pregnant women and children aged 12 and above, helping researchers gather evidence on groups that are frequently underrepresented in clinical trials.
The trial comes as the outbreak continues to place pressure on health services and emergency response teams. Figures released by organisations supporting the research indicated that DR Congo had recorded 9,552 cases and 4,602 deaths as of October 21.
The outbreak was declared on May 15, 2026, and prompted the WHO to declare a Public Health Emergency of International Concern. The spread of the virus beyond the initial outbreak area has also heightened concerns about cross-border transmission and the need for coordinated public health measures.
Bundibugyo is one of the virus species responsible for Ebola disease. The absence of an approved vaccine specifically for this strain has complicated efforts to control the current outbreak, making research into potential protection an urgent priority.
The WHO has stressed the importance of generating reliable scientific evidence rather than assuming that a vaccine approved against another strain will work against Bundibugyo.
The trial is supported by a wider partnership involving Congolese health authorities, research institutions and international organisations, including CEPI, which supports the development of vaccines against emerging infectious diseases.
For now, the start of the study does not mean that an effective vaccine against Bundibugyo has been confirmed. Researchers must evaluate the results before determining whether the candidates can provide meaningful protection.
The findings could nevertheless shape the response to the current outbreak and strengthen preparedness for future outbreaks involving the same strain. For communities affected by Ebola, the trial represents a significant research milestone, but controlling transmission will continue to depend on effective public health measures, surveillance, timely diagnosis and access to appropriate care.




